Volume : 13, Issue : 09, September – 2026

Title:

FORMULATION AND IN VITRO EVALUATION OF FLUCONAZOLE -LOADED SOLID LIPID NANOPARTICLES

Authors :

I Naramada*, Are Nikhil, Kolukunda Sarikha, Harkesh Singh, Mohd Zareef Khan, Sonam Rai

Abstract :

The present study was aimed to formulate and evaluate Fluconazole loaded solid lipid nanoparticles (SLNs) for improved antifungal activity and controlled drug delivery. Fluconazole is a widely used antifungal agent, but its conventional formulations may show limited penetration and reduced therapeutic effectiveness. Solid lipid nanoparticles were developed to enhance drug stability, entrapment efficiency, and sustained drug release. The prepared formulations were evaluated for important physicochemical parameters such as particle size, entrapment efficiency, zeta potential, and in-vitro drug release studies. The results showed that the particle size of the formulations ranged within the nanometer range and demonstrated good entrapment efficiency and stability. The in-vitro drug release study showed a sustained release pattern over a period of 12 hours. Among all the formulations, F4 was found to be the optimized formulation due to its smaller particle size, higher entrapment efficiency, and better drug release profile. Stability studies indicated that the optimized formulation remained stable under different storage conditions. From the results, it can be concluded that solid lipid nanoparticles are a promising drug delivery system for improving the therapeutic efficacy of paclitaxel in anticancer therapy.
Keywords: Fluconazole, Solid Lipid Nanoparticles, Antifungal activity, Drug Delivery System, Sustained Drug Release, Entrapment Efficiency.

Cite This Article:

Please cite this article in press I Narmada et al., Formulation And In Vitro Evaluation Of Fluconazole -Loaded Solid Lipid Nanoparticles.,. Indo Am. J. P. Sci, 2026; 13(09).

REFERENCES:

1. World Health Organization (WHO). Cancer Fact Sheet, 2023.
2. Bray F, et al. Global cancer statistics 2020: GLOBOCAN estimates. CA Cancer J Clin. 2021;71(3):209–249.
3. Kalyanaraman B. Teaching the basics of cancer metabolism. Free Radic Biol Med. 2017.
4. Chabner BA, Roberts TG. Chemotherapy and the war on cancer. Nat Rev Cancer. 2005.
5. Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2020.
6. Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2001;47:165–196.
7. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery. Eur J Pharm Biopharm. 2000;50:161–177.
8. Mukherjee S, Ray S, Thakur RS. Solid lipid nanoparticles: a modern formulation approach. Indian J Pharm Sci. 2009;71(4):349–358.
9. Souto EB, Müller RH. Lipid nanoparticles: effect on bioavailability and pharmacokinetics. Int J Pharm. 2010.
10. Pardeike J, Hommoss A, Müller RH. Lipid nanoparticles (SLN, NLC) in drug delivery. Int J Pharm. 2009.
11. Bhongiri B, Ramachandran V, Kumar RS. Preformulation studies of S-Equol. Journal of Pharmaceutical Negative Results. 2022;13(4):1020-9.
12. Ekambaram P, Sathali AA, Priyanka K. Solid lipid nanoparticles: a review. Sci Revs Chem Commun. 2012;2(1):80–102.
13. Wissing SA, Kayser O, Müller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev. 2004;56:1257–1272.
14. Das S, Chaudhury A. Recent advances in lipid nanoparticle formulations. J Control Release. 2011;146:1–10.
15. Ganesan P, Narayanasamy D. Lipid nanoparticles for drug delivery. Int J Pharm Investig. 2017;7(3):111–120.
16. Beloqui A, et al. Nanostructured lipid carriers for oral delivery. Nanomedicine. 2016;12:143–161.
17. Parveen R, Baboota S, Ali J, Ahuja A, Vasudev SS, Ahmad S. Preparation and evaluation of SLNs. AAPS PharmSciTech. 2009.
18. Shah R, Eldridge D, Palombo E, Harding I. Lipid nanoparticles: production and applications. Springer, 2015.